Abstract：
UNASSIGNED: Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).
UNASSIGNED: To assess the effectiveness and safety of upadacitinib through 48 weeks in real-world clinical practice for Japanese AD patients (aged ≥12 years).
UNASSIGNED: This retrospective study included 287 patients with moderate-to severe AD treated with 15 mg (n = 216) or 30 mg (n = 71) of upadacitinib daily. Effectiveness was assessed using eczema area severity index (EASI) scores, atopic dermatitis control tool (ADCT), peak pruritus-numerical rating scale (PP-NRS), and investigator\'s global assessment (IGA). Safety was evaluated through the incidence of treatment-emergent adverse events.
UNASSIGNED: From baseline, EASI, ADCT, PP-NRS, and IGA rapidly reduced at week 4, and the reduction was maintained until week 48 of treatment with upadacitinib at both doses. Achievement rates of EASI 75, EASI 90, and EASI 100 at week 48 were 63.5, 30.2, and 7.9 in 15 mg group, and 77.4, 54.8, and 3.2% in 30 mg group, respectively. Acne and herpes zoster were frequent, but no serious adverse events occurred.
UNASSIGNED: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.
UNASSIGNED: To assess the effectiveness and safety of upadacitinib through 48 weeks in real-world clinical practice for Japanese AD patients (aged ≥12 years).
UNASSIGNED: This retrospective study included 287 patients with moderate-to severe AD treated with 15 mg (n = 216) or 30 mg (n = 71) of upadacitinib daily. Effectiveness was assessed using eczema area severity index (EASI) scores, atopic dermatitis control tool (ADCT), peak pruritus-numerical rating scale (PP-NRS), and investigator\'s global assessment (IGA). Safety was evaluated through the incidence of treatment-emergent adverse events.
UNASSIGNED: From baseline, EASI, ADCT, PP-NRS, and IGA rapidly reduced at week 4, and the reduction was maintained until week 48 of treatment with upadacitinib at both doses. Achievement rates of EASI 75, EASI 90, and EASI 100 at week 48 were 63.5, 30.2, and 7.9 in 15 mg group, and 77.4, 54.8, and 3.2% in 30 mg group, respectively. Acne and herpes zoster were frequent, but no serious adverse events occurred.
UNASSIGNED: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.
摘要：
■先前的临床试验显示了Janus激酶1抑制剂upadacitinib治疗中重度特应性皮炎（AD）52周的疗效和安全性。
■评估upadacitinib在日本AD患者（年龄≥12岁）的实际临床实践中48周的有效性和安全性。
■这项回顾性研究包括287例中度至重度AD患者，每天接受15mg（n=216）或30mg（n=71）upadacitinib治疗。使用湿疹面积严重程度指数（EASI）评分评估有效性，特应性皮炎控制工具（ADCT），瘙痒峰-数字评定量表(PP-NRS)，和研究者的全球评估（IGA）。通过治疗引起的不良事件的发生率来评估安全性。
■从基线开始，EASI,ADCT,PP-NRS,和IGA在第4周时迅速降低,并维持至两种剂量的upadacitinib治疗第48周.在15mg组中，EASI75，EASI90和EASI100在第48周的成功率分别为63.5，30.2和7.9，30mg组分别为77.4、54.8和3.2%，分别。痤疮和带状疱疹经常发生，但未发生严重不良事件。
■Upadacitinib在实际临床实践中对中重度AD的治疗有效且可耐受48周。
■评估upadacitinib在日本AD患者（年龄≥12岁）的实际临床实践中48周的有效性和安全性。
■这项回顾性研究包括287例中度至重度AD患者，每天接受15mg（n=216）或30mg（n=71）upadacitinib治疗。使用湿疹面积严重程度指数（EASI）评分评估有效性，特应性皮炎控制工具（ADCT），瘙痒峰-数字评定量表(PP-NRS)，和研究者的全球评估（IGA）。通过治疗引起的不良事件的发生率来评估安全性。
■从基线开始，EASI,ADCT,PP-NRS,和IGA在第4周时迅速降低,并维持至两种剂量的upadacitinib治疗第48周.在15mg组中，EASI75，EASI90和EASI100在第48周的成功率分别为63.5，30.2和7.9，30mg组分别为77.4、54.8和3.2%，分别。痤疮和带状疱疹经常发生，但未发生严重不良事件。
■Upadacitinib在实际临床实践中对中重度AD的治疗有效且可耐受48周。
